Cancer exerts a profound impact on societies globally, and over the years, significant strides have been made in the field of cancer treatment. According to the World Health Organization (WHO), the number of individuals surviving post-cancer diagnosis has witnessed an upsurge, particularly with the advent and increased adoption of cancer biological therapies within the healthcare sector. This marks a substantial improvement compared to a time when such therapies were either unavailable or less prevalent.
In 2013, WHO reported that the average healing rate for males of all ages in the United States was 196.1. This statistic highlights the progress in cancer survivorship, indicative of the positive influence of cancer biological therapies. The global rate of cancer survivors is on an upward trajectory, and this trend is expected to persist, bolstering the expansion of the cancer biological therapies market.
The landscape of cancer treatment has evolved significantly, thanks to the innovations in biological therapies. These therapies, designed to target specific molecular and cellular components involved in cancer growth, have contributed to enhanced survival rates and improved overall outcomes for cancer patients. As a result, the number of individuals living beyond a cancer diagnosis has seen a notable increase.
Biological therapies, also known as immunotherapies, utilize the body's immune system to combat cancer cells. They represent a revolutionary approach in cancer treatment, offering a more targeted and precise method compared to conventional treatments like chemotherapy. By leveraging the body's own defense mechanisms, these therapies aim to selectively target cancer cells while minimizing damage to healthy tissues.
The global rise in cancer survival rates underscores the effectiveness and growing prominence of biological therapies. Patients undergoing these treatments often experience more favorable outcomes, contributing to the overall improvement in healing rates. The continuous advancement of cancer biological therapies and their increasing integration into mainstream healthcare practices are pivotal factors propelling the expansion of the market.
Moreover, the increasing prevalence of cancer has necessitated innovative and effective therapeutic solutions. Cancer, in its various forms, remains a significant global health concern, and the demand for advanced treatment options continues to escalate. Biological therapies, with their tailored and targeted approach, address this need, offering a ray of hope to individuals diagnosed with cancer.
As we move forward, the landscape of cancer care is likely to witness further transformations with ongoing research and development in the field of biological therapies. The collaborative efforts of the scientific community, pharmaceutical industry, and healthcare practitioners are instrumental in shaping the future of cancer treatment. The evolving paradigm of cancer biological therapies not only improves survival rates but also enhances the quality of life for cancer survivors, reflecting a positive trajectory in the global fight against cancer.
Carcinoid Syndrome Management Market Size was valued at USD 1.7 Billion in 2023. The Global Carcinoid Syndrome Management industry is projected to grow from USD 2.1 Billion in 2024 to USD 4.9 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.65% during the forecast period (2024 - 2032).
Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.
Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.
Study objectives:
Figure 1 Carcinoid Syndrome Management Market by Organs Affected
Key players profiled in the Carcinoid Syndrome Management Market are
The carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers.
The report for Carcinoid Syndrome Management by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Intended Audience
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)